Determining Which Patients Will Benefit from GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM

All Live and On-Demand Activities

Filter Activities

Clear

Interprofessional Perspectives on Safety Management With Targeted Therapy for B-cell Malignancies

1.00 hr(s) | ABIM , CME , MOC , NCPD

Specialty: B-cell Malignancies

Therapeutic Area(s): Hematology, Malignant , Oncology

Release Date: October 4, 2021

Expiration Date: October 3, 2022

Location: Internet Activity Enduring

In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

Ushering in A New Wave of Progress in Advanced Hepatobiliary Cancers: Expert Perspectives on Incorporating New Evidence and Innovative Therapeutics to Deliver Optimal, Patient-Centered Care

0.25 hr(s) | NCPD

Specialty: Hepatobiliary Cancers

Therapeutic Area(s): Oncology

Release Date: September 27, 2021

Expiration Date: September 26, 2022

Location: Internet Activity Enduring

After more than a decade of limited progress, the clinical management of advanced biliary tract cancers is rapidly changing. The introduction of new systemic therapies and the increased understanding of clinically actionable mutations in biliary tract cancers have led to the development of several biomarker-guided treatments and other promising strategies. In this activity, an oncology advanced practice provider discusses the latest clinical data regarding recently validated and forthcoming therapeutic strategies for patients with biliary tract cancers and the nurse’s role in improving patient outcomes through patient education, monitoring for and managing treatment-related toxicities, and counseling patients on therapeutic options, including clinical trial enrollment.

Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate-to-Severe Asthma

0.50 hr(s) | CME

Specialty: Asthma

Therapeutic Area(s): Pulmonology

Release Date: September 27, 2021

Expiration Date: September 26, 2022

Location: Internet Activity Enduring

In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma.

Secondary AML Through the Microscope: A Pathology-informed Guide to Modern Diagnostic and Treatment Principles

0.50 hr(s) | ABIM , ABPath , CC , CME , MOC

Specialty: AML

Therapeutic Area(s): Hematology, Malignant , Oncology

Release Date: September 20, 2021

Expiration Date: September 19, 2022

Location: Internet Activity Enduring

In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered.

Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations are Transforming Patient Care

0.50 hr(s) | CME

Specialty: Chronic Lymphocytic Leukemia (CLL)

Therapeutic Area(s): Chronic Lympoblastic Leukemia (CLL) , Hematology, Malignant , Oncology

Release Date: September 7, 2021

Expiration Date: September 6, 2022

Location: Internet Activity Enduring

Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care.

A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes

0.50 hr(s) | ABIM , CME , MOC , Royal College of Physicians and Surgeons of Canada

Specialty: Myelofibrosis

Therapeutic Area(s): Oncology

Release Date: August 25, 2021

Expiration Date: August 24, 2022

Location: Internet Activity Enduring

In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.

Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies

1.00 hr(s) | ILNA , NCPD

Specialty: AML

Release Date: August 18, 2021

Expiration Date: August 17, 2022

Location: Internet Activity Enduring

In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies.

Determining Which Patients Will Benefit from GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM

0.50 hr(s) | CME

Specialty: Diabetes

Therapeutic Area(s): Endocrinology

Release Date: July 16, 2021

Expiration Date: July 15, 2022

Location: Internet Activity Enduring

In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM.

1 3 4 5 6